Profile data is unavailable for this security.
About the company
Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (α particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.
- Revenue in JPY (TTM)269.49m
- Net income in JPY-759.81m
- Incorporated2007
- Employees44.00
- LocationStella Pharma Corp3-2-7, Koraibashi, Chuo-kuOSAKA-SHI 541-0043JapanJPN
- Phone+81 647071516
- Fax+81 647072077
- Websitehttps://stella-pharma.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kohjin Bio Co Ltd | -100.00bn | -100.00bn | 9.76bn | 159.00 | -- | 1.90 | -- | -- | -- | -- | -- | 1,003.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.82 | -- | 0.2942 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
| Solasia Pharma KK | 159.00m | -1.29bn | 10.47bn | 24.00 | -- | 4.87 | -- | 65.82 | -7.36 | -7.36 | 0.9065 | 9.85 | 0.0639 | 0.8549 | 0.5256 | 6,625,000.00 | -51.68 | -48.57 | -59.50 | -58.83 | 31.45 | 71.01 | -808.81 | -300.89 | 3.42 | -61.24 | 0.0219 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| Symbio Pharmaceuticals Ltd | 3.70bn | -3.42bn | 11.57bn | 109.00 | -- | 1.79 | -- | 3.13 | -81.51 | -81.51 | 87.41 | 140.73 | 0.4494 | 2.89 | 4.74 | 33,903,380.00 | -41.64 | -19.18 | -46.17 | -23.62 | 79.40 | 65.84 | -92.66 | -24.32 | 9.01 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| RaQualia Pharma Inc | 2.30bn | -673.00m | 12.07bn | 67.00 | -- | 2.14 | -- | 5.25 | -31.12 | -31.12 | 106.28 | 261.02 | 0.2652 | 3.82 | 2.89 | 34,300,980.00 | -7.77 | 2.13 | -8.56 | 2.26 | 84.78 | 88.49 | -29.28 | 5.32 | 3.55 | -- | 0.3972 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| ReproCell Inc | 2.49bn | -178.74m | 12.25bn | 96.00 | -- | 1.39 | -- | 4.92 | -2.03 | -2.03 | 28.72 | 93.57 | 0.2826 | 4.76 | 6.63 | 25,940,160.00 | -2.03 | -7.35 | -2.20 | -8.00 | 48.99 | 39.83 | -7.18 | -27.16 | 9.99 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| Oncolys Biopharma Inc | 31.38m | -1.82bn | 13.10bn | 34.00 | -- | 8.57 | -- | 417.26 | -95.02 | -95.02 | 1.62 | 67.90 | 0.0167 | 0.00 | 0.2245 | 923,058.80 | -97.25 | -45.75 | -116.54 | -51.86 | 0.00 | 60.46 | -5,813.82 | -233.66 | 7.01 | -- | 0.2052 | -- | -93.54 | -17.86 | -68.72 | -- | 28.18 | -- |
| Ohki Healthcare Holdings Co Ltd | 340.31bn | 2.08bn | 13.16bn | 632.00 | 6.17 | 0.4501 | 5.54 | 0.0387 | 151.56 | 151.56 | 24,771.52 | 2,077.28 | 2.54 | 13.31 | 4.54 | 538,470,000.00 | 1.49 | 1.85 | 6.44 | 8.42 | 5.11 | 6.16 | 0.5859 | 0.7178 | 0.8853 | -- | 0.1698 | 13.92 | 9.92 | 5.30 | 1.28 | 1.51 | -5.34 | 5.92 |
| Stella Pharma Corp | 269.49m | -759.81m | 18.11bn | 44.00 | -- | 6.43 | -- | 67.19 | -24.30 | -24.30 | 8.62 | 82.71 | 0.0594 | 0.0517 | 3.98 | 6,124,796.00 | -16.73 | -22.50 | -17.64 | -24.83 | 80.37 | -- | -281.94 | -488.65 | 15.60 | -943.38 | 0.2481 | -- | 17.65 | -- | 1.94 | -- | -5.87 | -- |
| TAIKO PHARMACEUTICAL CO LTD | 6.49bn | -2.33bn | 20.51bn | 208.00 | -- | 2.52 | -- | 3.16 | -46.91 | -46.91 | 130.40 | 160.86 | 0.4474 | 1.91 | 3.71 | 31,211,540.00 | -16.07 | -- | -19.68 | -- | 49.37 | -- | -35.92 | -- | 2.95 | -- | 0.2437 | -- | 21.43 | -- | 26.23 | -- | -- | -- |
| Astena Holdings Co Ltd | 53.22bn | 2.10bn | 21.15bn | 1.40k | 9.75 | 0.7188 | 4.86 | 0.3974 | 52.92 | 52.92 | 1,343.58 | 717.87 | 0.8105 | 3.42 | 2.73 | 37,904,980.00 | 3.18 | 2.49 | 5.77 | 4.44 | 33.18 | 25.33 | 3.93 | 2.32 | 0.889 | -- | 0.3439 | 44.92 | 4.73 | -2.85 | 100.61 | -3.85 | 38.54 | 11.38 |
| Fuso Pharmaceutical Industries Ltd | 56.52bn | 1.53bn | 21.15bn | 1.31k | 12.50 | 0.5132 | 5.61 | 0.3742 | 179.11 | 179.11 | 6,607.60 | 4,361.00 | 0.7454 | 3.08 | 2.35 | 43,245,600.00 | 2.02 | 1.91 | 3.50 | 3.09 | 25.67 | 26.92 | 2.71 | 2.69 | 0.9393 | 36.59 | 0.2767 | 41.10 | 8.61 | 3.76 | -14.21 | 9.02 | 9.13 | -2.64 |
| CanBas Co Ltd (Parent) | 0.00 | -1.21bn | 23.84bn | 12.00 | -- | 9.81 | -- | -- | -67.63 | -67.63 | 0.00 | 129.88 | 0.00 | -- | -- | -- | -53.54 | -62.25 | -56.62 | -70.91 | -- | -- | -- | -- | 25.09 | -- | -- | -- | -- | -- | 2.77 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Nikko Asset Management Co., Ltd.as of 30 Dec 2022 | 2.84m | 8.36% |
| Simplex Asset Management Co., Ltd.as of 05 Sep 2024 | 111.60k | 0.33% |
